Cynata Therapeutics Ltd has released a press release.
Cynata Receives $2.315m R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Cynata Therapeutics
- Approval of Clinical Trial of CYP-001 in Kidney Transplant
- Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment
- Strategic Review of Cynata Clinical Development Portfolio
- Cynata announces CEO succession and Board changes
- Cynata Completes Oversubscribed Share Purchase Plan
Later from Cynata Therapeutics
- Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
- Recruitment Completed in Phase 3 OA Clinical Trial
- Encouraging Initial Data from CYP-006TK DFU Trial
- First Patient Treated in Phase 2 GvHD Trial
- EU Approval for Phase 2 CYP-001 Trial in GvHD
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics